 "Cipla's US sales get boost with limited competition drugs")
Cipla is focusing on limited competition drugs to grow sales and offset price erosion in the US market.
The drugmaker on Friday said the US Food and Drug Administration had approved a generic version of anti-asthma drug Pulmicort Respules, which has an annual market size of $825 million. Only five companies sell the drug in the US. Anmol Ganjoo of J M Financial Securities estimates that Pulmicort Respules could contribute to around $40 million in sales and 5 per cent of Cipla’s earnings in FY19.
This is the second important approval for Cipla in recent weeks.
In October, it received the nod for a generic version of limited competition drug Renvela, used to treat kidney disease.
Cipla, Lupin out of Sensex
Cipla and Lupin have been dropped from the benchmark BSE Sensex. Private sector lenders IndusInd Bank and YES Bank will be the new entrants to the 30-share index. The changes will be effective from December 18, provider Asia Index, a joint venture between BSE and S&P Dow Jones, stated.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%